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Originally developed for the treatment of epilepsy, pregabalin has become a compound with a wide spectrum of
indications comprising anxiety disorders and chronic pain and is therefore largely prescribed. Thus, it is important
for clinicians to be aware of rare, but serious adverse effects. The following report illustrates the case of a 20-year-
old male with a severe depressive syndrome following pregabalin medication which even led to a suicide attempt.
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Pregabalin is a compound originally developed for treat-
ing epilepsy. Meanwhile, it has shown positive effects on
neuropathic pain as well as on general anxiety disorder
and is therefore largely prescribed by neurologists, psy-
chiatrists and, of course, general practitioners. Apart
from the most common side effects such as—among
others—drowsiness, increased appetite, and headache,
also depressive mood disorders must be kept in mind as
side effects of pregabalin and various other antiepileptic
drugs. An FDA warning concerning self-harm in patients
taking antiepileptic drugs was released in 2008 [1], yet a
relevant risk for pregabalin is postulated to be less than
1% [2] (low-risk group of antiepileptic compounds con-
cerning mood disorders). An observational study [2] did
not find a significant increase in self-harm within the
group of those low-risk compounds; however, a review
of the literature indicated that suicidal ideations under
pregabalin have recently been reported in one case [3]
under a daily dose of 600 mg pregabalin. The following
case is startling inasmuch as the patient did not only
experience suicidal ideations but did attempt suicide
while being prescribed pregabalin.Case presentation
The patient we present is a 20-year-old male admitted to
our psychiatric ward in February who reported depressed* Correspondence: andreas.kustermann@uk-erlangen.de
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article, unless otherwise stated.mood, loss of motivation, hopelessness, anxiety, sleep
disturbances, and suicidal thoughts as major depressive
symptoms.
Recent brain imaging, as well as routine laboratory
analysis upon admission, was unremarkable.
It was the patient’s first episode of a psychiatric dis-
order. It originally started with somatic symptoms and
their treatment. He suffered from an orofacial dyskinesia
of unknown origin, muscular atrophy of the right fore-
arm, and an alar scapula on the left, currently diagnosed
as multifocal motoric neuropathia. The orofacial dyskin-
esia was first treated symptomatically with tiapride start-
ing in July the year before admission, which he tolerated
well. Later, the movements were thought to be complex-
focal seizures, the medication was switched to pregaba-
lin, 150 mg daily within 2 weeks during his stay in an
external clinic in October. The patient reported no
further co-medication at that time.
Starting with the first prescription of pregabalin in
October, the patient felt increasingly depressed (visual
analogue scale 4/10–5/10) and demotivated. Suicidal
thoughts first appeared in November. These continued
to worsen and led to a suicide attempt in December of
the year before admission; he tried to poison himself to
death using high doses of ibuprofen and aspirin after
consuming alcohol. He could not name any triggering
factors and described the incident as a completely un-
expected and irrational act. He was seen by his general
practitioner and taken care of by his family. He did not
receive further inpatient treatment then but was pre-
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order to prevent further harmful acts on impulse. Later,
the serotonergic drug citalopram was added in order to
address the lack of motivation, starting with 10 mg and
rising to 20 mg in the morning. Tiapride was also
restarted for controlling the dyskinesia.
After the patient retrospectively clearly correlated the
start of pregabalin therapy with the onset of his depressive
symptoms during exploration on our ward, we immedi-
ately discontinued the drug. Consequently, he reported a
rapid decline in depressive symptoms, his mood remained
stable, and he was discharged. Until then, pregabalin was
not believed to trigger the patient’s symptoms, and his
somatic problems were the focus of investigation and
treatment. Thus, there are unfortunately no objective
follow-up scales available but only symptom descriptions.
His alcohol intake preceding the suicide attempt may be
considered a confounding factor. However, casual drink-
ing before taking the drug never caused suicidal thoughts
prior to this episode. The depressive symptoms them-
selves began only when the drug was started; thus, alcohol
might have had an aggravating effect.
Conclusions
For the clinician, the case illustrates that not only suicidal
ideations—a known but rare adverse effect of pregabalin—
but also suicidal actions under pregabalin therapy have to
be kept in mind. The issue that alcohol can reduce one’s
inhibitions to actually carry out suicidal ideations should
be separately addressed in the dialogue with the patient
and the combination with pregabalin should strictly be
advised against.
For theoretical considerations, it is quite surprising
that a compound relieving a patient from his anxious
distress sometimes does not improve mood and activity
but, on the contrary, causes severe depression and self-
harm tendencies. Taking into account that certain anti-
epileptic drugs have been shown to be protective for
patients with bipolar disorder concerning suicidality [4],
but hazardous for patients with monopolar depression,
for example [5], there may be critical patient variables
also for pregabalin which remain to be elucidated.
In the current case, pregabalin has been increased to
the daily dose of 150 mg within 2 weeks. In order to pre-
vent more common side effects of the compound such
as drowsiness or headache, a low starting dose which is
then gently increased often turns out to be helpful.
Maybe the initial dosing regimen also plays a role with
the depressive side effects.
Concerning the pharmacodynamic side of the mood
effects of antiepileptic drugs, serotonergic pathways are
discussed [6]. Regarding analgesic efficacy of pregabalin, it
has been shown to depend on the descending serotonergic
system with spinal 5HT3 receptors [7], so serotonergiceffects may also play a role for pregabalin-induced mood
alterations.
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